DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer

Status unconfirmed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic pancreatic cancer.

Key facts

Study ID

NCT00024375

Run by

Theradex

Starts

2001-06-01

Last updated by the study team

2009-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• NYU School of Medicine's Kaplan Comprehensive Cancer Center — New York, New York, United States
• Kimmel Cancer Center of Thomas Jefferson University - Philadelphia — Philadelphia, Pennsylvania, United States
• Virginia Mason Medical Center — Seattle, Washington, United States
• Kliniken Essen - Mitte — Essen, Germany
• Krankenhaus Nordwest — Frankfurt, Germany
• Erasmus Medical Center — Rotterdam, Netherlands
• New Cross Hospital — Wolverhampton, England, United Kingdom
• Beatson Oncology Centre — Glasgow, Scotland, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.